drugset / Trial / NCT06177522
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Phase 2
Not yet recruiting
30 enrolled
Jinling Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Clinical Study on the Safety and Efficacy of the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer
Timeline
- Start
- 2025-11-30
- Primary completion
- 2027-12-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Albumin-Bound Paclitaxel | Unknown | 125 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1 g | Intravenous |